Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia report.
B cells
SARS-CoV-2
T cells
antibodies
influenza
vaccines
viral infection
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
pubmed:
1
2
2023
medline:
28
3
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
Viruses infect millions of people each year. Both endemic viruses circulating throughout the population as well as novel epidemic and pandemic viruses pose ongoing threats to global public health. Developing more effective tools to address viruses requires not only in-depth knowledge of the virus itself but also of our immune system's response to infection. On June 29 to July 2, 2022, researchers met for the Keystone symposium "Viral Immunity: Basic Mechanisms and Therapeutic Applications." This report presents concise summaries from several of the symposium presenters.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-45Subventions
Organisme : NIAID NIH HHS
ID : U01 AI150747
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI154470
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00052
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI144616
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI163369
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132563
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI132132
Pays : United States
Informations de copyright
© 2023 New York Academy of Sciences.
Références
Nogusa, S., Thapa, R. J., Dillon, C. P., Liedmann, S., Oguin, T. H., Ingram, J. P., Rodriguez, D. A., Kosoff, R., Sharma, S., Sturm, O., Verbist, K., Gough, P. J., Bertin, J., Hartmann, B. M., Sealfon, S. C., Kaiser, W. J., Mocarski, E. S., López, C. B., Thomas, P. G., … Balachandran, S. (2016). RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus. Cell Host Microbe, 20, 13-24.
Thapa, R. J., Ingram, J. P., Ragan, K. B., Nogusa, S., Boyd, D. F., Benitez, A. A., Sridharan, H., Kosoff, R., Shubina, M., Landsteiner, V. J., Andrake, M., Vogel, P., Sigal, L. J., Tenoever, B. R., Thomas, P. G., Upton, J. W., & Balachandran, S. (2016). DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe, 20, 674-681.
Zhang, T., Yin, C., Boyd, D. F., Quarato, G., Ingram, J. P., Shubina, M., Ragan, K. B., Ishizuka, T., Crawford, J. C., Tummers, B., Rodriguez, D. A., Xue, J., Peri, S., Kaiser, W. J., López, C. B., Xu, Y., Upton, J. W., Thomas, P. G., Green, D. R., & Balachandran, S. (2020). Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell, 180, 1115-1129.e13.
Shubina, M., Tummers, B., Boyd, D. F., Zhang, T., Yin, C., Gautam, A., Guo, X.-Z. J., Rodriguez, D. A., Kaiser, W. J., Vogel, P., Green, D. R., Thomas, P. G., & Balachandran, S. (2020). Necroptosis restricts influenza A virus as a stand-alone cell death mechanism. Journal of Experimental Medicine, 217, e20191259.
Wu, T. T.-H., Travaglini, K. J., Rustagi, A., Wu, T. T.-H., Travaglini, K. J., Rustagi, A., Xu, D., Zhang, Y., Jang, S. K., Gillich, A., Dehghannasiri, R., Martinez-Colon, G., Beck, A., Wilk, A. J., Morri, M., Trope, W. L., Shrager, J. B., Quake, S. R., Kuo, C. S., … Salzman, J. (2022). Activated interstitial macrophages are a predominant target of viral takeover and focus of inflammation in COVID-19 initiation in human lung. bioRxiv, 2022.05.10.491266.
Frere, J. J., Serafini, R. A., Pryce, K. D., Frere, J. J., Serafini, R. A., Pryce, K. D., Zazhytska, M., Oishi, K., Golynker, I., Panis, M., Zimering, J., Horiuchi, S., Hoagland, D. A., Møller, R., Ruiz, A., Overdevest, J. B., Kodra, A., Canoll, P. D., Goldman, J. E., … tenOever, B. R. (2022). SARS-CoV-2 infection results in lasting and systemic perturbations post recovery. bioRxiv, 2022.01.18.476786.
Serafini, R. A., Frere, J. J., Zimering, J., Zimering, J., Giosan, I. M., Pryce, K. D., Golynker, I., Panis, M., Ruiz, A., tenOever, B., & Zachariou, V. (2022). SARS-CoV-2 airway infection results in time-dependent sensory abnormalities in a hamster model. bioRxiv, 2022.08.19.504551.
Strampe, J., Asogun, D. A., Speranza, E., Pahlmann, M., Soucy, A., Bockholt, S., Pallasch, E., Becker-Ziaja, B., Duraffour, S., Bhadelia, N., Ighodalo, Y., Oyakhilome, J., Omomoh, E. O., Olokor, T., Adomeh, D. I., Ikponwonsa, O., Aire, C., Tobin, E., Akpede, N., … Oestereich, L. (2021). Factors associated with progression to death in patients with lassa fever in Nigeria: An observational study. Lancet Infectious Diseases, 21, 876-886.
Moses, M. E., Hofmeyr, S., Cannon, J. L., Andrews, A., Gridley, R., Hinga, M., Leyba, K., Pribisova, A., Surjadidjaja, V., Tasnim, H., & Forrest, S. (2021). Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection. PLoS Computational Biology, 17, e1009735.
Ahmed, S. S., Schur, P. H., Macdonald, N. E., & Steinman, L. (2014). A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. Journal of Autoimmunity, 50, 1-11.
Vogel, G. (2015). Influenza. Narcolepsy link to pandemic flu vaccine becomes clearer. Science, 349, 17.
Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.-L., Hublin, C., Julkunen, I., Olsén, P., Saarenpää-Heikkilä, O., & Kilpi, T. (2012). AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One, 7, e33536.
Han, F., Lin, L., Warby, S. C., Faraco, J., Li, J., Dong, S. X., An, P., Zhao, L., Wang, L. H., Li, Q. Y., Yan, H., Gao, Z. C., Yuan, Y., Strohl, K. P., & Mignot, E. (2011). Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of Neurology, 70, 410-417.
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., Mccausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., Mehta, A., Razavi, B., Del Rio, C., Zheng, N.-Y., Lee, J.-H., Huang, M., Ali, Z., Kaur, K., Andrews, S., … Wilson, P. C. (2011). Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine, 208, 181-193.
Pica, N., Hai, R., Krammer, F., Wang, T. T., Maamary, J., Eggink, D., Tan, G. S., Krause, J. C., Moran, T., Stein, C. R., Banach, D., Wrammert, J., Belshe, R. B., García-Sastre, A., & Palese, P. (2012). Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proceedings of the National Academy of Sciences of the United States of America, 109, 2573-2578.
Thomson, C. A., Wang, Y., Jackson, L. M., Olson, M., Wang, W., Liavonchanka, A., Keleta, L., Silva, V., Diederich, S., Jones, R. B., Gubbay, J., Pasick, J., Petric, M., Jean, F., Allen, V. G., Brown, E. G., Rini, J. M., & Schrader, J. W. (2012). Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Frontiers in Immunology, 3, 87.
Sangster, M. Y., Baer, J., Santiago, F. W., Fitzgerald, T., Ilyushina, N. A., Sundararajan, A., Henn, A. D., Krammer, F., Yang, H., Luke, C. J., Zand, M. S., Wright, P. F., Treanor, J. J., Topham, D. J., & Subbarao, K. (2013). B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clinical and Vaccine Immunology, 20, 867-876.
Li, G.-M., Chiu, C., Wrammert, J., Mccausland, M., Andrews, S. F., Zheng, N.-Y., Lee, J.-H., Huang, M., Qu, X., Edupuganti, S., Mulligan, M., Das, S. R., Yewdell, J. W., Mehta, A. K., Wilson, P. C., & Ahmed, R. (2012). Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 9047-9052.
Andrews, S. F., Huang, Y., Kaur, K., Popova, L. I., Ho, I. Y., Pauli, N. T., Dunand, C. J. H., Taylor, W. M., Lim, S., Huang, M., Qu, X., Lee, J.-H., Salgado-Ferrer, M., Krammer, F., Palese, P., Wrammert, J., Ahmed, R., & Wilson, P. C. (2015). Immune history profoundly affects broadly protective B cell responses to influenza. Science Translational Medicine, 7, 316ra192.
Bajic, G., van der Poel, C. E., Kuraoka, M., Schmidt, A. G., Carroll, M. C., Kelsoe, G., & Harrison, S. C. (2019). Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies. Scientific Reports, 9, 3492.
Khurana, S., Hahn, M., Klenow, L., & Golding, H. (2020). Autoreactivity of broadly neutralizing influenza human antibodies to human tissues and human proteins. Viruses, 12, 1140.
Guthmiller, J. J., Lan, L. Y.-L., Fernández-Quintero, M. L., Han, J., Utset, H. A., Bitar, D. J., Hamel, N. J., Stovicek, O., Li, L., Tepora, M., Henry, C., Neu, K. E., Dugan, H. L., Borowska, M. T., Chen, Y.-Q., Liu, S. T. H., Stamper, C. T., Zheng, N.-Y., Huang, M., … Wilson, P. C. (2020). Polyreactive broadly neutralizing B cells are selected to provide defense against pandemic threat influenza viruses. Immunity, 53, 1230-1244.e5.
Keating, R., Hertz, T., Wehenkel, M., Harris, T. L., Edwards, B. A., Mcclaren, J. L., Brown, S. A., Surman, S., Wilson, Z. S., Bradley, P., Hurwitz, J., Chi, H., Doherty, P. C., Thomas, P. G., & Mcgargill, M. A. (2013). The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nature Immunology, 14, 1266-1276.
Labombarde, J. G., Pillai, M. R., Wehenkel, M., Lin, C.-Y., Keating, R., Brown, S. A., Crawford, J. C., Brice, D. C., Castellaw, A. H., Mandarano, A. H., Guy, C. S., Mejia, J. R., Lewis, C. D., Chang, T.-C., Oshansky, C. M., Wong, S.-S., Webby, R. J., Yan, M., Li, Q.-Z., … Mcgargill, M. A. (2022). Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. Cell Reports, 38, 110482.
Mobasheri, L., Nasirpour, M. H., Masoumi, E., Azarnaminy, A. F., Jafari, M., & Esmaeili, S.-A. (2022). SARS-CoV-2 triggering autoimmune diseases. Cytokine, 154, 155873.
Mateus, J., Dan, J. M., Zhang, Z., Rydyznski Moderbacher, C., Lammers, M., Goodwin, B., Sette, A., Crotty, S., & Weiskopf, D. (2021). Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science, 374, eabj9853.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., Nakao, C., Rayaprolu, V., Rawlings, S. A., Peters, B., Krammer, F., Simon, V., Saphire, E. O., Smith, D. M., Weiskopf, D., … Crotty, S. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 371, eabf4063.
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., Sidney, J., Filaci, G., Weiskopf, D., Da Silva Antunes, R., Crotty, S., Grifoni, A., & Sette, A. (2022). SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 185, 847-859.e11.
Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Cortes, F. H., Grifoni, A., Tarke, A., Chang, J., Escarrega, E. A., Kim, C., Goodwin, B., Bloom, N. I., Frazier, A., Weiskopf, D., Sette, A., & Crotty, S. (2022). Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 185, 2434-2451.e17.
Pogorelyy, M. V., Rosati, E., Minervina, A. A., Mettelman, R. C., Scheffold, A., Franke, A., Bacher, P., & Thomas, P. G. (2022). Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery. Cell Reports Medicine, 3, 100697.
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., Wullimann, D. J., Kammann, T., Emgård, J., Parrot, T., Folkesson, E., Rooyackers, O., Eriksson, L. I., Henter, J.-I., Sönnerborg, A., … Unge, C. (2020). Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell, 183, 158-168.e14.
Bacher, P., Rosati, E., Esser, D., Martini, G. R., Saggau, C., Schiminsky, E., Dargvainiene, J., Schröder, I., Wieters, I., Khodamoradi, Y., Eberhardt, F., Vehreschild, M. J. G. T., Neb, H., Sonntagbauer, M., Conrad, C., Tran, F., Rosenstiel, P., Markewitz, R., Wandinger, K.-P., … Scheffold, A. (2020). Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity, 53, 1258-1271.e5.
Weiskopf, D., Schmitz, K. S., Raadsen, M. P., Grifoni, A., Okba, N. M. A., Endeman, H., van den Akker, J. P. C., Molenkamp, R., Koopmans, M. P. G., Van Gorp, E. C. M., Haagmans, B. L., De Swart, R. L., Sette, A., & de Vries, R. D. (2020). Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science Immunology, 5, eabd2071.
Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., Traenkle, B., Kaiser, P. D., Rothbauer, U., Becker, M., Junker, D., Krause, G., Strengert, M., … Walz, J. S. (2021). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Science Immunology, 22, 74-85.
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., Marrama, D., de Silva, A. M., Frazier, A., Carlin, A. F., Greenbaum, J. A., Peters, B., Krammer, F., Smith, D. M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 181, 1489-1501.e15.
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., Chia, W. N., Chen, M. I.-C., Wang, L.-F., Ooi, E. E., Kalimuddin, S., Tambyah, P. A., Low, J. G-H., Tan, Y.-J., & Bertoletti, A. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 584, 457-462.
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., Mallal, S., Lammers, M., Rubiro, P., Quiambao, L., Sutherland, A., Yu, E. D., Da Silva Antunes, R., Greenbaum, J., Frazier, A., … Weiskopf, D. (2020). Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science, 370, 89-94.
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., … Thiel, A. (2020). SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 587, 270-274.
Low, J. S., Vaqueirinho, D., Mele, F., Foglierini, M., Jerak, J., Perotti, M., Jarrossay, D., Jovic, S., Perez, L., Cacciatore, R., Terrot, T., Pellanda, A. F., Biggiogero, M., Garzoni, C., Ferrari, P., Ceschi, A., Lanzavecchia, A., Sallusto, F., & Cassotta, A. (2021). Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science, 372, 1336-1341.
Niessl, J., Sekine, T., Lange, J., Konya, V., Forkel, M., Maric, J., Rao, A., Mazzurana, L., Kokkinou, E., Weigel, W., Llewellyn-Lacey, S., Hodcroft, E. B., Karlsson, A. C., Fehrm, J., Sundman, J., Price, D. A., Mjösberg, J., Friberg, D., & Buggert, M. (2021). Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. Science Immunology, 6, eabk0894.
Minervina, A. A., Pogorelyy, M. V., Kirk, A. M., Crawford, J. C., Allen, E. K., Chou, C.-H., Mettelman, R. C., Allison, K. J., Lin, C.-Y., Brice, D. C., Zhu, X., Vegesana, K., Wu, G., Trivedi, S., Kottapalli, P., Darnell, D., Mcneely, S., Olsen, S. R., Schultz-Cherry, S., … Thomas, P. G. (2022). SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nature Immunology, 23, 781-790.
Mudd, P. A., Minervina, A. A., Pogorelyy, M. V., Turner, J. S., Kim, W., Kalaidina, E., Petersen, J., Schmitz, A. J., Lei, T., Haile, A., Kirk, A. M., Mettelman, R. C., Crawford, J. C., Nguyen, T. H. O., Rowntree, L. C., Rosati, E., Richards, K. A., Sant, A. J., Klebert, M. K., … Whitt, K. (2022). SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 185, 603-613.e15.
Schattgen, S. A., Guion, K., Crawford, J. C., Souquette, A., Barrio, A. M., Stubbington, M. J. T., Thomas, P. G., & Bradley, P. (2022). Integrating T cell receptor sequences and transcriptional profiles by clonotype neighbor graph analysis (CoNGA). Nature Biotechnology, 40, 54-63.
Cross, R. W., Hastie, K. M., Mire, C. E., Robinson, J. E., Geisbert, T. W., Branco, L. M., Ollmann Saphire, E., & Garry, R. F. (2019). Antibody therapy for Lassa fever. Current Opinion in Virology, 37, 97-104.
Burton, D. R. (2002). Antibodies, viruses and vaccines. Nature Reviews Immunology, 2, 706-713.
Robinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. A., Garry, C. E., Bradley, B. T., Yu, H., Shaffer, J. G., Boisen, M. L., Hartnett, J. N., Zandonatti, M. A., Rowland, M. M., Heinrich, M. L., Martínez-Sobrido, L., Cheng, B., … Garry, R. F. (2016). Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 7, 11544.
Cohen, C. A., Li, A. P. Y., Hachim, A., Hui, D. S. C., Kwan, M. Y. W., Tsang, O. T. Y., Chiu, S. S., Chan, W. H., Yau, Y. S., Kavian, N., Ma, F. N. L., Lau, E. H. Y., Cheng, S. M. S., Poon, L. L. M., Peiris, M., & Valkenburg, S. A. (2021). SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nature Communications, 12, 4678.
Hachim, A., Kavian, N., Cohen, C. A., Chin, A. W. H., Chu, D. K. W., Mok, C. K. P., Tsang, O. T. Y., Yeung, Y. C., Perera, R. A. P. M., Poon, L. L. M., Peiris, J. S. M., & Valkenburg, S. A. (2020). ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nature Immunology, 21, 1293-1301.
Hachim, A., Gu, H., Kavian, O., Mori, M., Kwan, M. Y. W., Chan, W. H., Yau, Y. S., Chiu, S. S., Tsang, O. T. Y., Hui, D. S. C., Mok, C. K. P., Ma, F. N. L., Lau, E. H. Y., Amarasinghe, G. K., Qavi, A. J., Cheng, S. M. S., Poon, L. L. M., Peiris, J. S. M., Valkenburg, S. A., & Kavian, N. (2022). SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nature Communications, 13, 2951.
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K.-O., Yiu, K., Chan, T.-O., Bull, M., Ling, K. C., Dai, Z., Ng, S. S., Lui, G. C.-Y., Wu, C., Amarasinghe, G. K., Leung, D. W., Wong, S. Y. S., Valkenburg, S. A., Peiris, M., & Hui, D. S. (2022). Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology, 27, 301-310.
Eguia, R. T., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2021). A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathogens, 17, e1009453.
Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021). Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Science Translational Medicine, 13, eabi9915.
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., Dingens, A. S., Nargi, R. S., Sutton, R. E., Suryadevara, N., Rothlauf, P. W., Liu, Z., Whelan, S. P. J., Carnahan, R. H., Crowe, J. E., & Bloom, J. D. (2021). Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe, 29, 44-57.e9.
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022). An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. Virus Evolution, 8, veac021.
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Finkin, S., Hägglöf, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., … Bjorkman, P. J. (2020). Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell, 182, 828-842.e16.
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J. (2020). SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 588, 682-687.
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S., Kakutani, L. M., Keeffe, J. R., Wu, H.-J., Howarth, M., West, A. P., Barnes, C. O., Nussenzweig, M. C., & Bjorkman, P. J. (2021). Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 371, 735-741.
Cohen, A. A., Van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., Kakutani, L. M., West, A. P., Saturday, G., Lee, Y. E., Gao, H., Jette, C. A., Lewis, M. G., Tan, T. K., Townsend, A. R., … Bjorkman, P. J. (2022). Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 377, eabq0839.
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., Chik, K. K.-H., Yuen, T. T.-T., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Yuen, K.-Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 604, 553-556.
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., Yu, J., Chik, K. K.-H., Yuen, T. T.-T., Yoon, C., To, K. K.-W., Chen, H., Yin, M. T., Sobieszczyk, M. E., Huang, Y., … Ho, D. D. (2022). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 602, 676-681.
Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D., Chang, J. Y., Shah, J. G., Nguyen, N., Chen, Z., Meyers, K., Yin, M. T., Sobieszczyk, M. E., Sheng, Z., Huang, Y., Liu, L., & Ho, D. D. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature, 608, 603-608.
Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., Wählby Hamrén, U., Mankad, V. S., Ren, P., Takas, T., Abram, M. E., Leach, A., Griffin, M. P., & Villafana, T. (2022). Nirsevimab for prevention of RSV in healthy late-preterm and term infants. New England Journal of Medicine, 386, 837-846.
GSK. GSK starts phase 3 study of RSV maternal candidate vaccine. https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/
GSK. GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-its-respiratory-syncytial-virus-rsv-vaccine-candidate-for-older-adults/
Graham, B. S. (2017). Vaccine development for respiratory syncytial virus. Current Opinion in Virology, 23, 107-112.
Battles, M. B., Más, V., Olmedillas, E., Cano, O., Vázquez, M., Rodríguez, L., Melero, J. A., & Mclellan, J. S. (2017). Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nature Communications, 8, 1528.
Mas, V., Nair, H., Campbell, H., Melero, J. A., & Williams, T. C. (2018). Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine, 36, 6660-6673.
Más, V., Rodriguez, L., Olmedillas, E., Cano, O., Palomo, C., Terrón, M. C., Luque, D., Melero, J. A., & Mclellan, J. S. (2016). Engineering, structure and immunogenicity of the human metapneumovirus F protein in the postfusion conformation. PLoS Pathogens, 12, e1005859.
Rappazzo, C. G., Hsieh, C.-L., Rush, S. A., Esterman, E. S., Delgado, T., Geoghegan, J. C., Wec, A. Z., Sakharkar, M., Más, V., McLellan, J. S., & Walker, L. M. (2022). Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. Immunity, 55, 1710-1724.e8.
Lessler, J., Chaisson, L. H., Kucirka, L. M., Bi, Q., Grantz, K., Salje, H., Carcelen, A. C., Ott, C. T., Sheffield, J. S., Ferguson, N. M., Cummings, D. A. T., Metcalf, C. J. E., & Rodriguez-Barraquer, I. (2016). Assessing the global threat from Zika virus. Science, 353, aaf8160.
Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.-M., Haouz, A., England, P., Stiasny, K., Mongkolsapaya, J., Heinz, F. X., Screaton, G. R., & Rey, F. A. (2016). Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature, 536, 48-53.
Elong Ngono, A., & Shresta, S. (2018). Immune response to dengue and Zika. Annual Review of Immunology, 36, 279-308.
Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G., Gordon, A., Balmaseda, A., & Harris, E. (2017). Antibody-dependent enhancement of severe dengue disease in humans. Science, 358, 929-932.
Crooks, C. M., Weiler, A. M., Rybarczyk, S. L., Bliss, M. I., Jaeger, A. S., Murphy, M. E., Simmons, H. A., Mejia, A., Fritsch, M. K., Hayes, J. M., Eickhoff, J. C., Mitzey, A. M., Razo, E., Braun, K. M., Brown, E. A., Yamamoto, K., Shepherd, P. M., Possell, A., Weaver, K., … Aliota, M. T. (2021). Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. PLoS Neglected Tropical Diseases, 15, e0009641.
Katzelnick, L. C., Bos, S., & Harris, E. (2020). Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. Current Opinion in Virology, 43, 59-70.
Katzelnick, L. C., Narvaez, C., Arguello, S., Lopez Mercado, B., Collado, D., Ampie, O., Elizondo, D., Miranda, T., Bustos Carillo, F., Mercado, J. C., Latta, K., Schiller, A., Segovia-Chumbez, B., Ojeda, S., Sanchez, N., Plazaola, M., Coloma, J., Halloran, M. E., Premkumar, L., … Harris, E. (2020). Zika virus infection enhances future risk of severe dengue disease. Science, 369, 1123-1128.
Clemens, E. A., Holbrook, B. C., Kanekiyo, M., Yewdell, J. W., Graham, B. S., & Alexander-Miller, M. A. (2021). An R848-conjugated influenza virus vaccine elicits robust immunoglobulin G to hemagglutinin stem in a newborn nonhuman primate model. Journal of Infectious Diseases, 224, 351-359.
Crofts, K. F., Holbrook, B. C., D'Agostino, R. B., & Alexander-Miller, M. A. (2022). Analysis of R848 as an adjuvant to improve inactivated influenza vaccine immunogenicity in elderly nonhuman primates. Vaccines, 10, 494.
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Lier, M., Dopfer-Jablonka, A., Jäck, H.-M., Behrens, G. M. N., & Pöhlmann, S. (2022). The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell, 185, 447-456.e11.
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., Winkler, M. S., Schulz, S., Jäck, H.-M., Jahrsdörfer, B., Schrezenmeier, H., Müller, M., Kleger, A., Münch, J., & Pöhlmann, S. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 184, 2384-2393.e12.
Lamers, M. M., Mykytyn, A. Z., Breugem, T. I., Groen, N., Knoops, K., Schipper, D., van Acker, R., van den Doel, P. B., Bestebroer, T., Koopman, C. D., Reusken, C., Muraro, M. J., GeurtsvanKessel, C. H., van Royen, M. E., Peters, P. J., Zhang, J., & Haagmans, B. L. (2022). SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium. bioRxiv, 2022.01.19.476898.
Arora, P., Zhang, L., Krüger, N., Rocha, C., Sidarovich, A., Schulz, S., Kempf, A., Graichen, L., Moldenhauer, A.-S., Cossmann, A., Dopfer-Jablonka, A., Behrens, G. M. N., Jäck, H.-M., Pöhlmann, S., & Hoffmann, M. (2022). SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe, 30, 1103-1111.e6.
Hoffmann, M., Sidarovich, A., Arora, P., Krüger, N., Nehlmeier, I., Kempf, A., Graichen, L., Winkler, M. S., Niemeyer, D., Goffinet, C., Drosten, C., Schulz, S., Jäck, H.-M., & Pöhlmann, S. (2022). Evidence for an ACE2-independent entry pathway that can protect from neutralization by an antibody used for COVID-19 therapy. mBio, 13, e0036422.
Couch, R. B., Bayas, J. M., Caso, C., Mbawuike, I. N., López, C. N., Claeys, C., El Idrissi, M., Hervé, C., Laupèze, B., Oostvogels, L., & Moris, P. (2014). Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infectious Diseases, 14, 425.
Monto, A. S., Petrie, J. G., Cross, R. T., Johnson, E., Liu, M., Zhong, W., Levine, M., Katz, J. M., & Ohmit, S. E. (2015). Antibody to influenza virus neuraminidase: An independent correlate of protection. Journal of Infectious Diseases, 212, 1191-1199.
Wohlbold, T. J., Nachbagauer, R., Xu, H., Tan, G. S., Hirsh, A., Brokstad, K. A., Cox, R. J., Palese, P., & Krammer, F. (2015). Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio, 6, e02556.
Chen, Y.-Q., Wohlbold, T. J., Zheng, N.-Y., Huang, M., Huang, Y., Neu, K. E., Lee, J., Wan, H., Rojas, K. T., Kirkpatrick, E., Henry, C., Palm, A.-K. E., Stamper, C. T., Lan, L. Y.-L., Topham, D. J., Treanor, J., Wrammert, J., Ahmed, R., Eichelberger, M. C., … Wilson, P. C. (2018). Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell, 173, 417-429.e10.
Mcmahon, M., Kirkpatrick, E., Stadlbauer, D., Strohmeier, S., Bouvier, N. M., & Krammer, F. (2019). Mucosal immunity against neuraminidase prevents influenza B virus transmission in guinea pigs. mBio, 10, e00560-19.
Strohmeier, S., Amanat, F., Zhu, X., Mcmahon, M., Deming, M. E., Pasetti, M. F., Neuzil, K. M., Wilson, I. A., & Krammer, F. (2021). A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio, 12, e0224121.
Nelson, S. A., Richards, K. A., Glover, M. A., Chaves, F. A., Crank, M. C., Graham, B. S., Kanekiyo, M., & Sant, A. J. (2022). CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines. NPJ Vaccines, 7, 124.
Xu, L., Pegu, A., Rao, E., Doria-Rose, N., Beninga, J., Mckee, K., Lord, D. M., Wei, R. R., Deng, G., Louder, M., Schmidt, S. D., Mankoff, Z., Wu, L., Asokan, M., Beil, C., Lange, C., Leuschner, W. D., Kruip, J., Sendak, R., … Nabel, G. J. (2017). Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 358, 85-90.
Pegu, A., Xu, L., Demouth, M. E., Fabozzi, G., March, K., Almasri, C. G., Cully, M. D., Wang, K., Yang, E. S., Dias, J., Fennessey, C. M., Hataye, J., Wei, R. R., Rao, E., Casazza, J. P., Promsote, W., Asokan, M., Mckee, K., Schmidt, S. D., … Mascola, J. R. (2022). Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Report, 38, 110199.
Misasi, J., Wei, R. R., Wang, L., Pegu, A., Wei, C.-J., Oloniniyi, O. K., Zhou, T., Moliva, J. I., Zhao, B., Choe, M., Yang, E. S., Zhang, Y., Boruszczak, M., Chen, M., Leung, K., Li, J., Yang, Z.-Y., Andersen, H., Carlton, K., … Sullivan, N. J. (2022). A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape. bioRxiv, 2022.07.29.502029.
Honce, R., & Schultz-Cherry, S. (2019). Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Frontiers in Immunology, 10, 1071.
O'brien, K. B., Vogel, P., Duan, S., Govorkova, E. A., Webby, R. J., Mccullers, J. A., & Schultz-Cherry, S. (2012). Impaired wound healing predisposes obese mice to severe influenza virus infection. Journal of Infectious Diseases, 205, 252-261.
Karlsson, E. A., Meliopoulos, V. A., van de Velde, N. C., Van De Velde, L.-A., Mann, B., Gao, G., Rosch, J., Tuomanen, E., Mccullers, J., Vogel, P., & Schultz-Cherry, S. (2017). A perfect storm: Increased colonization and failure of vaccination leads to severe secondary bacterial infection in influenza virus-infected obese mice. mBio, 8, e00889-17.
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz-Cherry, S. (2021). Influenza virus and SARS-CoV-2: Pathogenesis and host responses in the respiratory tract. Nature Reviews Microbiology, 19, 425-441.
Honce, R., Karlsson, E. A., Wohlgemuth, N., Estrada, L. D., Meliopoulos, V. A., Yao, J., & Schultz-Cherry, S. (2020). Obesity-related microenvironment promotes emergence of virulent influenza virus strains. mBio, 11, e03341-19.
Karlsson, E. A., Hertz, T., Johnson, C., Mehle, A., Krammer, F., & Schultz-Cherry, S. (2016). Obesity outweighs protection conferred by adjuvanted influenza vaccination. mBio, 7, e01144-16.
Honce, R., Vazquez-Pagan, A., Livingston, B., Cherry, S., Hargest, V., Sharp, B., van de Velde, L.-A., Skinner, R. C., Thomas, P. G., & Schultz-Cherry, S. (2022). Improved metabolic syndrome and timing of weight loss is crucial for influenza vaccine-induced immunity in obese mice. bioRxiv, 2022.04.16.488487.
Smith, M., Honce, R., & Schultz-Cherry, S. (2020). Metabolic syndrome and viral pathogenesis: Lessons from influenza and coronaviruses. Journal of Virology, 94, e00665-20.